Monte Rosa Therapeutics announced data for MRT-8102, its NEK7-directed molecular glue degrader, showing positive impact on biomarkers linked to atherosclerotic cardiovascular disease
BiotechTV - News
00:00
Molecular Glue Selectivity Builds Pharma Confidence
Markus Warmuth says cellular profiling demonstrates monoselective degradation and improved safety, helping pharmaceutical companies embrace molecular glue degraders.
Play episode from 03:51
Transcript
